allows sufficient Mcl-1 phosphorylation and degradation to trigger apoptosis. Thus, the APC/C, a major effector of the spindle assembly checkpoint (SAC), not only ensures cell cycle arrest upon spindle disruption, but promotes cell death when the duration of mitotic arrest is too long.
Apoptotic cell death proceeds through a series of signalling events that bring about the dismantling of cellular components by a family of cysteine proteases, the caspases. In particular, genotoxic and/or cytotoxic stress promotes the release of cytochrome c, a component of the electron transport chain in the mitochondria, to the cytoplasm, which in turn triggers activation of the initiator and executioner caspases, caspase-9 and caspase-3, respectively. It is well recognized that a failure in cell cycle progression, such as prolonged mitotic arrest, can induce apoptosis by triggering mitochondrial cytochrome c release. When a cell encounters a defect in mitotic spindle assembly (as when cells are treated with microtubule poisons), entry into anaphase is inhibited by the SAC that suppresses APC/C-mediated cyclin B1 degradation until metaphase can be completed; if the spindle defect is unrepairable, apoptotic cell death ensues. Cyclin B1 degradation is slowed, but not halted, during prolonged mitotic arrest because of residual APC/C Cdc20 activity. As a result, when CDK1 activity drops below the threshold required for maintenance of mitosis, cells eventually exit M phase with a defect in chromosome segregation. Thus, mitotic cell death seems to be a preventive mechanism that avoids the creation of carcinogenic aneuploids. Harley et al (2010) now show that the degradation of the anti-apoptotic Bcl-2 family member Mcl-1 has an important function in such mitotic cell death. Cytochrome c release is regulated by the balance of pro-and anti-apoptotic Bcl-2 family proteins. Owing to its very short half-life (o0.5 h), Mcl-1 protein levels, and its consequent contribution to cell survival, can be rapidly tuned by changes in protein stability. degradation and loss of CDK1 activity. Thus, cells are not unduly susceptible to apoptosis if mitosis proceeds normally. However, on prolonged SAC arrest with sustained CDK1/ cyclin B1 activity, the accrued phosphorylation promotes sufficient degradation to drop Mcl-1 below the threshold necessary to sustain cell viability. This ensures that only prolonged arrest induces apoptosis.
B Arrested mitosis
The mechanism of mitotic cell death has long been unclear. A recent study showed that Bcl-x L and Bcl-2 are phosphorylated by CDK1/cyclin B1 and inhibited in mitosis (Terrano et al, 2010) . However, it has also been shown that CDK1 activity is required to protect cells from apoptosis in mitosis (O'Connor et al, 2002) . How can we reconcile these apparently paradoxical results? In contrast to prolonged mitotic arrest, cells in normal mitosis exhibit resistance to apoptosis. For instance, during M phase, caspase-2 and caspase-9 are inhibited by CDK1/cyclin B1-mediated phosphorylation, thus preventing apoptosis (Allan and Clarke, 2007; Andersen et al, 2009) .
The findings by Harley et al (2010) provide new insight into the CDK1/cyclin B1-mediated regulation of pro-and antiapoptotic proteins in mitosis. It is suggested that during mitosis in which high CDK1/cyclin B1 activity is maintained, the anti-apoptotic function of Bcl-x L and Bcl-2 is suppressed, whereas Mcl-1 is gradually degraded ( Figure 1A) . Concomitantly, CDK1/cyclin B1 inhibits the activation of the initiator caspase-2 and caspase-9, thereby preventing the full initiation of the apoptotic cascade ( Figure 1A ). When mitotic arrest is protracted, the loss of Mcl-1 ultimately elicits the release of cytochrome c from the mitochondria ( Figure 1B) . Interestingly, the authors show that during mitotic arrest, Mcl-1 degradation precedes the dephosphorylation of caspase-9. In that a non-phosphorylatable mutant of caspase-2 or caspase-9 can enhance sensitivity to apoptosis in mitotic cells (Allan and Clarke, 2007; Andersen et al, 2009) , it is likely that a signal distinct from Mcl-1 degradation also takes part in mitotic cell death through the dephosphorylation of the caspases. Lastly, it is known that some cancer cells overexpress Mcl-1, whereas others do not (Warr and Shore, 2008; Schwickart et al, 2010) . It will be interesting to compare the efficacy of microtubule-directed chemotherapeutics in cancers expressing varying levels of Mcl-1 in that this may serve as a novel biomarker to predict patient responsiveness to these agents.
